A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Best
O G
OG
Gardiner
A C
AC
Majid
A
A
Walewska
R
R
Austen
B
B
Skowronska
A
A
Ibbotson
R
R
Stankovic
T
T
Dyer
M J S
MJ
Oscier
D G
DG
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D064007:Ataxia Telangiectasia Mutated Proteins; D018797:Cell Cycle Proteins / Q000235:genetics*; D050759:Cyclin-Dependent Kinase Inhibitor p21 / Q000235:genetics; D004268:DNA-Binding Proteins / Q000235:genetics*; D005047:Etoposide / Q000008:administration & dosage*; D016158:Genes, p53; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics*; D009154:Mutation; D010879:Piperazines / Q000008:administration & dosage*; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*; D025521:Tumor Suppressor Proteins / Q000235:genetics*
C493956:CDKN1A protein, human; D018797:Cell Cycle Proteins; D050759:Cyclin-Dependent Kinase Inhibitor p21; D004268:DNA-Binding Proteins; D007093:Imidazoles; D010879:Piperazines; D025521:Tumor Suppressor Proteins; C482205:nutlin 3; D005047:Etoposide; C576324:ATM protein, human; D064007:Ataxia Telangiectasia Mutated Proteins; D017346:Protein Serine-Threonine Kinases